InsiderTrades.com logo
Carole Huntsman net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Carole Huntsman Biography and Net Worth

Chief Commercial Officer of Madrigal Pharmaceuticals

Ms. Huntsman has more than 30 years of biopharmaceutical experience with 35 launches across immunology, neurology, oncology, rare diseases, and rare blood disorders. Prior to joining Madrigal, she served as the Senior Vice President, Head of Specialty Care North America and the U.S. Country Lead at Sanofi, where she was responsible for many specialty product launches, including the U.S. Launch of Dupixent. She held commercial roles of increasing responsibility at Sanofi Genzyme, EMD Serono, Pfizer and Muro Pharmaceuticals. Prior to joining the biopharmaceutical industry, Ms. Huntsman served as an officer in the U.S. Army.

What is Carole Huntsman's net worth?

The estimated net worth of Carole Huntsman is at least $3.42 million as of January 24th, 2025. Ms. Huntsman owns 10,438 shares of Madrigal Pharmaceuticals stock worth more than $3,422,307 as of March 28th. This net worth approximation does not reflect any other investments that Ms. Huntsman may own. Learn More about Carole Huntsman's net worth.

How do I contact Carole Huntsman?

The corporate mailing address for Ms. Huntsman and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at ir@madrigalpharma.com. Learn More on Carole Huntsman's contact information.

Has Carole Huntsman been buying or selling shares of Madrigal Pharmaceuticals?

In the last ninety days, Carole Huntsman has sold $116,328.28 of Madrigal Pharmaceuticals stock. Most recently, Carole Huntsman sold 347 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $335.24, for a transaction totalling $116,328.28. Following the completion of the sale, the insider now directly owns 10,438 shares of the company's stock, valued at $3,499,235.12. Learn More on Carole Huntsman's trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Fred Craves (Director), James Daly (Director), Paul Friedman (Director), Carole Huntsman (Chief Commercial Officer), Shannon Kelley (General Counsel), Richard Levy (Director), Brian Lynch (SVP), William Sibold (CEO), Remy Sukhija (Sr. VP & Chief Commercial Officer), Rebecca Taub (Director, Founder, Chief Medical Officer and President of Research & Development), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, insiders at the biopharmaceutical company sold shares 25 times. They sold a total of 228,184 shares worth more than $55,041,951.49. The most recent insider tranaction occured on March, 5th when VP Robert E Waltermire sold 14,113 shares worth more than $4,817,049.16. Insiders at Madrigal Pharmaceuticals own 22.8% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 3/5/2025.

Carole Huntsman Insider Trading History at Madrigal Pharmaceuticals

See Full Table

Carole Huntsman Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows Carole Huntsman's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$116ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k-$50k$0$50k$100kTotal Insider BuyingTotal Insider Selling

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $327.87
Low: $324.02
High: $336.79

50 Day Range

MA: $332.93
Low: $293.64
High: $355.88

2 Week Range

Now: $327.87
Low: $189.00
High: $377.46

Volume

195,806 shs

Average Volume

391,905 shs

Market Capitalization

$7.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A